Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions

British Journal of Ophthalmology

Volumn 91, Issue 10, 2007, Pages 1318-1322

  Lux, Anja ^a,b   Llacer, Helene ^a,b   Heussen, Florian M A ^a,b   Joussen, Antonio M ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; READING; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; EDEMA; FLUORESCEIN ANGIOGRAPHY; FOVEA CENTRALIS; HUMANS; INJECTIONS; PROSPECTIVE STUDIES; READING; RETINAL DISEASES; TREATMENT FAILURE; VISUAL ACUITY;

EID: 34848817406     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.113902     Document Type: Article

References (13)

1. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
2. Brown DM, Kaiser PK, Michels M, et al. ANCHOR study group: Ranibizumab vs. verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
3. Ladewig MS, Ziemssen F, Jaissle G, et al. Intravitreales Bevacizumab bei der neovasculären altersbedingten Maculadegeneration. Der Ophthalmologe Online first: 6 May, 2006.
4. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular generation. Retina 2006;26:495-511.
5. Ferris FL, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6.
6. Radner W, Willinger U, Obermayer W, et al. Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit. Klin Monatsbl Augenheilkd 1998;213:174-81.
7. Stifter E, Konig F, Lang T, et al. Reliability of a standardized reading chart system: variance component analysis, test-retest and inter-chart reliability. Graefes Arch Clin Exp Ophthalmol 2004;242:31-9.
8. Barbazetto I, Burdan A, Bressler NM, et al. Treatment of age-related macular degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment: TAP and VIP report No. 2. Arch Ophthalmol 2003;121:1253-68.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ramibizumab for age-related macular generation, MARINA study. N Engl J Med 2006;355:1419-31.
10. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularisation caused by ARMD (IbeNA Study). Results of a phase 1 escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-78.
11. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol Online First: 18 Nov, 2006.
12. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol Online First: 28 Sep, 2006.
13. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61.